Cyclacel Narrows Loss Amid Strategic Pivot, Proposed Merger

Ticker: BGMSP · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 1130166

Sentiment: mixed

Topics: Biotechnology, Mergers and Acquisitions, Reverse Stock Split, Strategic Alternatives, Pharmaceuticals, Clinical Trials, Corporate Restructuring

Related Tickers: CYCC, CYCCP, BGMS, 9318.KL

TL;DR

**Cyclacel is ditching its pharma roots for a Malaysian fire safety and waste management play, a desperate Hail Mary that might just save it from the Nasdaq delisting graveyard.**

AI Summary

Cyclacel Pharmaceuticals, Inc. reported a net loss of $1.399 million for the six months ended June 30, 2025, a significant improvement from the $6.203 million net loss in the same period of 2024. This improvement was primarily driven by a $4.947 million gain on the deconsolidation of its wholly-owned UK subsidiary, Cyclacel Limited, on January 31, 2025. Revenue from clinical trial supply remained negligible at $0 for the six months ended June 30, 2025, down from $33,000 in 2024. Operating expenses decreased substantially, with research and development falling to $890,000 in 2025 from $4.825 million in 2024, and general and administrative expenses increasing to $5.463 million from $3.207 million. The company's cash and cash equivalents increased to $4.275 million as of June 30, 2025, from $3.137 million at December 31, 2024, largely due to $5.526 million in financing activities. Strategic changes include focusing solely on the plogosertib clinical program and a proposed merger with FITTERS Diversified Berhad, which would rename the company Bio Green Med Solution, Inc. and list under the ticker BGMS.

Why It Matters

This 10-Q signals a dramatic shift for Cyclacel, moving from a struggling biopharmaceutical company to a potential new entity focused on fire safety and 'Waste-To-Resource' services via the FITTERS merger. For investors, the proposed transaction with FITTERS Diversified Berhad is a make-or-break moment, fundamentally altering the company's business model and competitive landscape. Existing employees and customers of Cyclacel's biopharma programs face uncertainty, as the fadraciclib program is being marketed for sale and the company is narrowing its focus to plogosertib. The broader market will watch to see if this strategic pivot can salvage shareholder value, especially given the significant reverse stock splits and the company's historical losses.

Risk Assessment

Risk Level: high — The company faces high risk due to its ongoing net losses, with a $1.399 million net loss for the six months ended June 30, 2025, and a history of significant losses. The proposed merger with FITTERS Diversified Berhad represents a complete change in business model, introducing new operational and market risks. Furthermore, the company executed two reverse stock splits (one-for-sixteen and one-for-fifteen) in May and July 2025, often a sign of a company struggling to maintain its listing requirements.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the proposed merger with FITTERS Diversified Berhad, as it represents a complete business model transformation. Current shareholders should consider the dilution risk and the viability of the new business focus, while potential investors should await further details on the combined entity's strategy and financial projections before committing capital.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$1.399M
eps
N/A
gross Margin
N/A
cash Position
$4.275M
revenue Growth
-100.0%

Revenue Breakdown

SegmentRevenueGrowth
Clinical Trial Supply$0-100.0%

Key Numbers

Key Players & Entities

FAQ

What were Cyclacel Pharmaceuticals' key financial results for the six months ended June 30, 2025?

Cyclacel Pharmaceuticals reported a net loss of $1.399 million for the six months ended June 30, 2025, a significant improvement from the $6.203 million net loss in the prior year. Cash and cash equivalents increased to $4.275 million.

What strategic changes did Cyclacel Pharmaceuticals implement in early 2025?

In early 2025, Cyclacel Pharmaceuticals liquidated its UK subsidiary, Cyclacel Limited, resulting in a $4.947 million gain on deconsolidation. The company also decided to focus solely on the plogosertib clinical program and is exploring a merger with FITTERS Diversified Berhad.

Who is Datuk Dr. Doris Wong Sing Ee and what is her role in Cyclacel Pharmaceuticals?

Datuk Dr. Doris Wong Sing Ee is an investor who purchased 1,000,000 shares of Series C Convertible Preferred Stock and 1,745,262 shares of Series D Convertible Preferred Stock from David E. Lazar, ultimately converting them into 810,952 shares of Cyclacel's Common Stock, giving her 70% of the fully diluted shares.

What is the proposed merger with FITTERS Diversified Berhad and its implications for Cyclacel?

The proposed merger involves Cyclacel exchanging common stock for all ordinary shares of Fitters Sdn. Bhd., a subsidiary of FITTERS Diversified Berhad. Cyclacel will pay up to $1,000,000 in cash and issue 19.99% of its common stock, with Cyclacel stockholders owning approximately 80.01% of the combined company, which will be renamed Bio Green Med Solution, Inc. and trade as BGMS.

Why did Cyclacel Pharmaceuticals perform reverse stock splits in 2025?

Cyclacel Pharmaceuticals effected a one-for-sixteen reverse stock split on May 12, 2025, and a further one-for-fifteen reverse stock split on July 7, 2025. These actions are typically taken to increase the per-share price of a company's stock to meet minimum listing requirements on exchanges like Nasdaq.

What happened to Cyclacel Limited, the UK subsidiary?

Cyclacel Limited, the company's wholly-owned UK subsidiary, entered into a creditors voluntary liquidation on January 24, 2025. This resulted in the deconsolidation of its financial results from Cyclacel Pharmaceuticals as of January 31, 2025, and a gain on deconsolidation of approximately $4.947 million.

What are the current drug development focuses for Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has determined to focus solely on the development of the plogosertib ('Plogo') clinical program. The fadraciclib drug development program, previously owned by Cyclacel Limited, is being marketed for sale by the joint liquidator, and Cyclacel has no plans to repurchase its rights.

What is the significance of BIGM Capital SDN. BHD for Cyclacel Pharmaceuticals?

BIGM Capital SDN. BHD is a new fully owned subsidiary incorporated by Cyclacel Pharmaceuticals on June 5, 2025, in Malaysia. While it has yet to commence trading, its incorporation suggests a strategic move to establish a presence in Malaysia, potentially related to the proposed merger with FITTERS Diversified Berhad.

How did Cyclacel Pharmaceuticals' operating expenses change year-over-year?

For the six months ended June 30, 2025, research and development expenses decreased significantly to $890,000 from $4.825 million in 2024. However, general and administrative expenses increased to $5.463 million in 2025 from $3.207 million in 2024.

What are the conditions for the termination of the Exchange Agreement with FITTERS Diversified Berhad?

Both Cyclacel and FITTERS Diversified Berhad have the right to terminate the Exchange Agreement if the closing date of the Transaction has not occurred on or before September 30, 2025. The transaction is also subject to approval from Cyclacel stockholders and FITTERS shareholders.

Risk Factors

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Cyclacel operate in a competitive landscape where success hinges on the efficacy and market potential of novel drug candidates. The industry is also subject to evolving healthcare policies and reimbursement landscapes.

Regulatory Implications

Cyclacel's operations are subject to stringent regulations by bodies like the FDA. The success of its plogosertib program depends on navigating complex clinical trial protocols and obtaining regulatory approval, which carries inherent risks of delays or outright rejection.

What Investors Should Do

  1. Monitor the progress and outcome of the proposed merger with FITTERS Diversified Berhad.
  2. Closely track the development and clinical trial results for plogosertib.
  3. Evaluate the company's cash burn rate and future financing needs.
  4. Assess the impact of increased G&A expenses on operational efficiency.

Key Dates

Glossary

Deconsolidation
The process of removing a subsidiary from a parent company's consolidated financial statements. This typically occurs when the parent company no longer has control over the subsidiary. (A $4.947 million gain was recognized by Cyclacel due to the deconsolidation of its UK subsidiary, significantly impacting its net loss for the period.)
Convertible Preferred Stock
A class of preferred stock that can be converted into a specified number of common stock shares at the option of the holder. (The company issued Series C and Series D Convertible Preferred Stock to investors, which were later converted into common stock, affecting share structure and ownership.)
Plogosertib
A specific clinical program or drug candidate being developed by Cyclacel Pharmaceuticals. (Cyclacel is focusing its strategy solely on the plogosertib clinical program, making its success critical for the company's future.)
Securities Purchase Agreement
A contract between a seller and a buyer for the purchase and sale of securities. (The company entered into such agreements with investors David E. Lazar and Datuk Dr. Doris Wong Sing Ee, impacting its capital structure and ownership.)
Clinical Trial Supply
The provision of drug substances or finished drug products for use in clinical trials. (Revenue from this segment was $0 for the six months ended June 30, 2025, indicating a lack of current commercial activity in this area.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, Cyclacel Pharmaceuticals reported a net loss of $1.399 million, a substantial improvement from the $6.203 million net loss in the same period of 2024. This was largely due to a $4.947 million gain on deconsolidation, as revenue from clinical trial supply dropped to $0 from $33,000. Operating expenses saw a significant decrease in R&D ($890K vs $4.825M) but an increase in G&A ($5.463M vs $3.207M).

Filing Stats: 4,801 words · 19 min read · ~16 pages · Grade level 16.9 · Accepted 2025-08-13 21:45:43

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION: Item 1.

Financial Statements

Financial Statements: F-1 Balance Sheets as of June 30, 2025 and December 31, 2024 (unaudited) F-1 F-2 Consolidated Statements of Comprehensive Loss F-3 F-4 F-5

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited) F-6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 4 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 12 Item 4.

Controls and Procedures

Controls and Procedures 12

- OTHER INFORMATION

PART II - OTHER INFORMATION: Item 1.

Legal Proceedings

Legal Proceedings 13 Item 1A.

Risk Factors

Risk Factors 13 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 13 Item 3. Defaults Upon Senior Securities 13 Item 4. Mine Safety Disclosures 13 Item 5. Other Information 13 Item 6. Exhibits 13 SIGNATURE PAGE 14 2 Recent Developments In December 2024, Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the "Company") announced that it was in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor, David E. Lazar of Activist Investing, LLC ("Lazar"). The Company's Board of Directors (the "Board") reviewed a range of appropriate strategies to realize value from its assets. The Board directed management to reduce operating costs, which included the liquidation of the Company's wholly-owned United Kingdom subsidiary, Cyclacel Limited ("Subsidiary"), while such alternatives were being explored. On January 2, 2025, the Company entered into a securities purchase agreement with Lazar, pursuant to which he agreed to purchase from the Company 1,000,000 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel at a purchase price of $1.00 per share for aggregate gross proceeds of $3.1 million, D Convertible Preferred Stock are the "Securities"). The proceeds of the transaction were used to settle outstanding liabilities of the Company and other general corporate and operating purposes. On February 11, 2025, investor Lazar, who was serving as the Company's interim Chief Executive Officer and Secretary, entered into a securities purchase agreement (the "Purchase Agreement") with an investor, Datuk Dr. Doris Wong Sing Ee (the "Investor") pursuant to which the Investor agreed to purchase 1,000,000 shares of Series C

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing